Abstract
Objectives
We report a first experience involving the use of 90Y radiolabelled microspheres (TheraSphere) for the treatment of mainly primary hepatic tumours.
Materials and methods
Treatment using TheraSphere microspheres was planned in 15 patients (13 with hepatocellular carcinoma, 2 with neuroendocrine tumour metastases). The treatment was preceded by a first angiography aimed at embolizing the vascularizing arterial branches of other structures outside the liver and evaluating the percentage of pulmonary shunt by scintiscanning after perfusion with 99mTc-MAA. The objective of the treatment carried out during a second angiography was to deliver a dose of 120±20 Gy (mean±SD) to the target hepatic volume.
Results
Technical difficulties were encountered in embolizing gastroduodenal or gastric branches in two patients and in one patient these led to cancellation of the treatment. A total of 14 patients were treated with an average activity of 3.18 GBq. In one patient, the injection was defective (stagnation of microspheres at the outlet of the catheter). SPECT/CT acquisitions provided important information in four patients (visualization of the gallbladder in three; visualization of the stomach in one, leading to a new coiling). The average exposure of the nuclear medicine physician carrying out the injections was 64±80 µSv at the fingers. A partial response was seen in six patients, stabilization in five and progression in three. One patient presented with a gastric ulcer and two showed an increase in their hepatocellular insufficiency.
Conclusion
Although sometimes technically difficult, the use of TheraSphere microspheres is a worthwhile therapeutic approach because of the low level exposure of operators and the encouraging rate of response or stabilization. The use of SPECT/CT contributes greatly to helping therapeutic planning, especially in the learning curve or when the angiographic procedure is difficult.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Garin E, Bourguet P. Radiolipiodol of liver tumors. Use of labelled lipiodol in the treatment of hepatic tumors. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd ed, vol 1. Edinburgh: Elsevier Science; 2004. p. 473–483.
Raoul JL, Boucher E, Olivier D, Guilligomar’ch A, Boudjema K, Garin E. Association of cisplatin (CDDP) and intraarterial injection of 131I-lipiodol in the treatment of hepatocellular carcinoma: results of a phase II trial. Int J Radiat Oncol Biol Phys 2006;64(3):745–50.
Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782–7.
Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156–61.
Houle S, Yip TCK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, et al. Hepatocellular carcinoma: a pilot trial of treatment with Y-90 microspheres. Radiology 1989;172:857–60.
Shepherd FA, Rotstein LE, Houle S, Yip TCK, Paul K, Sniderman KW. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992;70:2250–4.
Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002;13(9 Pt 2):S223–9.
Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006;17(8):1251–78.
Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005;16(7):911–35.
Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA Jr, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007;30(4):571–92.
Garin E, Laffont S, Rolland Y, Olivie D, Lecloirec J, Herry JY, et al. Safe radiation exposure of medical personnel using simple radioprotection means while administering 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun 2003;24:671–8.
Ho S, Lau JWY, Leung TWT. Intrahepatic 90Y-microspheres for hepatocellular carcinoma. J Nucl Med 2001;42:1587–9.
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004;60(5):1552–63.
Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005;16(12):1627–39.
Risse JH, Grünvald F, Kersjes W, Strunk H, Caselman WH, Palmedo H, et al. Intraarterial HCC therapy with I-131-Lipiodol. Cancer Biother Radiopharm 2000;15:65–71.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garin, E., Rolland, Y., Boucher, E. et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging 37, 453–461 (2010). https://doi.org/10.1007/s00259-009-1279-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-009-1279-6